BACKGROUND: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death with a 5-year survival of only 21%. Reliable prognostic and/or predictive biomarkers are needed to improve NSCLC patient stratification, particularly in curative disease stages. Since the endogenous cannabinoid system is involved in both carcinogenesis and anticancer immune defense, we hypothesized that tumor tissue expression of cannabinoid 1 and 2 receptors (CB1 and CB2) may affect survival. METHODS: Tumor tissue samples collected from 100 NSCLC patients undergoing radical surgery were analyzed for CB1 and CB2 gene and protein expression using the quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). The gene and protein expression data were correlated with disease stage, histology, tumor grading, application of chemotherapy, and survival. Additional paired tumor and normal tissue samples of 10 NSCLC patients were analyzed independently for comparative analysis of CB1 and CB2 gene expression. RESULTS: Patients with tumors expressing the CB2 gene had significantly longer overall survival (OS) (P<0.001), cancer specific survival (CSS) (P=0.002), and disease-free survival (DFS) (P<0.001). They also presented with fewer lymph node metastases at the time of surgery (P=0.011). A multivariate analysis identified CB2 tumor tissue gene expression as a positive prognostic factor for CSS [hazard ratio (HR) =0.274; P=0.013] and DFS (HR =0.322; P=0.009), and increased CSS. High CB2 gene and protein expression were detected in 79.6% and 31.5% of the tested tumor tissue samples, respectively. Neither CB1 gene nor CB1 or CB2 protein expression affected survival. When comparing paired tumor and tumor-free lung tissue samples, we observed reduced CB1 (P=0.008) and CB1 (P=0.056) gene expression in tumor tissues. CONCLUSIONS: In NSCLC patients undergoing radical surgery, expression of the CB1 and CB2 receptor genes is significantly decreased in neoplastic versus tumor-free lung tissue. CB2 tumor tissue gene expression is strongly associated with longer survival (OS, CSS, DFS) and fewer lymph node metastases at the time of surgery. More studies are needed to evaluate its role as a biomarker in NSCLC and to investigate the potential use of CB2 modulators to treat or prevent lung cancers.

1 Department of Surgery University Hospital Olomouc Olomouc Czech Republic

Cancer Research Czech Republic Olomouc Czech Republic

Department of Anesthesiology Landesklinikum Amstetten Amstetten Austria

Institute of Molecular and Clinical Pathology and Medical Genetics Faculty of Medicine University of Ostrava Ostrava Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University and University Hospital in Olomouc Olomouc Czech Republic

Ringerike Hospital Hønefoss Norway

Tomas Bata Regional Hospital in Zlin Zlin Czech Republic

Zobrazit více v PubMed

Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019;69:363-85. 10.3322/caac.21565 PubMed DOI

Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57. 10.1378/chest.122.3.1037 PubMed DOI

Chudacek J, Bohanes T, Klein J, et al. Detection of minimal residual disease in lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014;158:189-93. 10.5507/bp.2013.019 PubMed DOI

Gachechiladze M, Škarda J, Skanderová D, et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. Lung Cancer 2020;147:30-8. 10.1016/j.lungcan.2020.06.025 PubMed DOI

Solomon B. Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC. J Thorac Oncol 2017;12:9-11. 10.1016/j.jtho.2016.11.2214 PubMed DOI

Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4. 10.1038/346561a0 PubMed DOI

Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5. 10.1038/365061a0 PubMed DOI

Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462. 10.1124/pr.58.3.2 PubMed DOI PMC

Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9. 10.1126/science.1470919 PubMed DOI

Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90. 10.1016/0006-2952(95)00109-D PubMed DOI

Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397-411. 10.1111/j.1476-5381.2008.00048.x PubMed DOI PMC

Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97. 10.1006/bbrc.1995.2437 PubMed DOI

Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry 2016;79:516-25. 10.1016/j.biopsych.2015.07.028 PubMed DOI PMC

Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61. 10.1111/j.1432-1033.1995.tb20780.x PubMed DOI

Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010;160:467-79. 10.1111/j.1476-5381.2010.00729.x PubMed DOI PMC

De Jesús ML, Hostalot C, Garibi JM, et al. Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochem Int 2010;56:829-33. 10.1016/j.neuint.2010.03.007 PubMed DOI

Caffarel MM, Andradas C, Mira E, et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 2010;9:196. 10.1186/1476-4598-9-196 PubMed DOI PMC

Pérez-Gómez E, Andradas C, Blasco-Benito S, et al. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. J Natl Cancer Inst 2015;107:djv077. 10.1093/jnci/djv077 PubMed DOI

Martínez-Martínez E, Gómez I, Martín P, et al. Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience 2015;2:131-41. 10.18632/oncoscience.119 PubMed DOI PMC

Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006;171:31-8. 10.1016/j.cancergencyto.2006.06.014 PubMed DOI

Fraguas-Sánchez AI, Martín-Sabroso C, Torres-Suárez AI. Insights into the effects of the endocannabinoid system in cancer: a review. Br J Pharmacol 2018;175:2566-80. 10.1111/bph.14331 PubMed DOI PMC

Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev 2011;30:599-612. 10.1007/s10555-011-9318-8 PubMed DOI PMC

Ladin DA, Soliman E, Griffin L, et al. Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. Front Pharmacol 2016;7:361. 10.3389/fphar.2016.00361 PubMed DOI PMC

Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012;12:436-44. 10.1038/nrc3247 PubMed DOI

Boyacıoğlu Ö, Bilgiç E, Varan C, et al. ACPA decreases non-small cell lung cancer line growth through Akt/PI3K and JNK pathways in vitro. Cell Death Dis 2021;12:56. 10.1038/s41419-020-03274-3 PubMed DOI PMC

Dhopeshwarkar A, Mackie K. CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? Mol Pharmacol 2014;86:430-7. 10.1124/mol.114.094649 PubMed DOI PMC

Velasco G, Hernández-Tiedra S, Dávila D, et al. The use of cannabinoids as anticancer agents. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:259-66. 10.1016/j.pnpbp.2015.05.010 PubMed DOI

Vidinský B, Gál P, Pilátová M, et al. Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation. Folia Biol (Praha) 2012;58:75-80. PubMed

Preet A, Ganju RK, Groopman JE. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008;27:339-46. 10.1038/sj.onc.1210641 PubMed DOI

Preet A, Qamri Z, Nasser MW, et al. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) 2011;4:65-75. 10.1158/1940-6207.CAPR-10-0181 PubMed DOI PMC

Ravi J, Elbaz M, Wani NA, et al. Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway. Mol Carcinog 2016;55:2063-76. 10.1002/mc.22451 PubMed DOI PMC

Ravi J, Sneh A, Shilo K, et al. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget 2014;5:2475-86. 10.18632/oncotarget.1723 PubMed DOI PMC

Milian L, Mata M, Alcacer J, et al. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PloS One 2020;15:e0228909. 10.1371/journal.pone.0228909 PubMed DOI PMC

Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801. 10.6004/jnccn.2010.0056 PubMed DOI

Lausen B, Schumacher M. Maximally Selected Rank Statistics. Biometrics 1992;48:73-85. 10.2307/2532740 DOI

Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Computational Statistics & Data Analysis 2003;43:121-37. 10.1016/S0167-9473(02)00225-6 DOI

Rossi F, Punzo F, Umano GR, et al. Role of Cannabinoids in Obesity. Int J Mol Sci 2018;19:2690. 10.3390/ijms19092690 PubMed DOI PMC

Verty AN, Stefanidis A, McAinch AJ, et al. Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice. PloS One 2015;10:e0140592. 10.1371/journal.pone.0140592 PubMed DOI PMC

Ramer R, Heinemann K, Merkord J, et al. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 2013;12:69-82. 10.1158/1535-7163.MCT-12-0335 PubMed DOI

Bremnes RM, Al-Shibli K, Donnem T, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 2011;6:824-33. 10.1097/JTO.0b013e3182037b76 PubMed DOI

Qamri Z, Preet A, Nasser MW, et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 2009;8:3117-29. 10.1158/1535-7163.MCT-09-0448 PubMed DOI PMC

Casanova ML, Blázquez C, Martínez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003;111:43-50. 10.1172/JCI200316116 PubMed DOI PMC

McKallip RJ, Lombard C, Fisher M, et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002;100:627-34. 10.1182/blood-2002-01-0098 PubMed DOI

Cianchi F, Papucci L, Schiavone N, et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res 2008;14:7691-700. 10.1158/1078-0432.CCR-08-0799 PubMed DOI

Adinolfi B, Romanini A, Vanni A, et al. Anticancer activity of anandamide in human cutaneous melanoma cells. Eur J Pharmacol 2013;718:154-9. 10.1016/j.ejphar.2013.08.039 PubMed DOI

Orellana-Serradell O, Poblete CE, Sanchez C, et al. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol Rep 2015;33:1599-608. 10.3892/or.2015.3746 PubMed DOI PMC

Wallander ML, Geiersbach KB, Tripp SR, et al. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 2012;136:796-803. 10.5858/arpa.2011-0321-OA PubMed DOI

Börner C, Martella E, Höllt V, et al. Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2’-deoxycytidine. Neuroimmunomodulation 2012;19:180-6. 10.1159/000331474 PubMed DOI

Möhnle P, Schütz SV, Schmidt M, et al. MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure. Biochem Biophys Res Commun 2014;451:516-21. 10.1016/j.bbrc.2014.08.008 PubMed DOI

Tegeder I. Endocannabinoids as Guardians of Metastasis. Int J Mol Sci 2016;17:230. 10.3390/ijms17020230 PubMed DOI PMC

Thors L, Bergh A, Persson E, et al. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PloS One 2010;5:e12275. 10.1371/journal.pone.0012275 PubMed DOI PMC

Shubbar E, Helou K, Kovács A, et al. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. BMC Cancer 2013;13:47. 10.1186/1471-2407-13-47 PubMed DOI PMC

Winkler K, Ramer R, Dithmer S, et al. Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells. Oncotarget 2016;7:15047-64. 10.18632/oncotarget.7592 PubMed DOI PMC

Morphine Analgesia, Cannabinoid Receptor 2, and Opioid Growth Factor Receptor Cancer Tissue Expression Improve Survival after Pancreatic Cancer Surgery

Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patients